Table 2 Histopathological and clinical parameters of patients subjected to paired analysis of galectin-1 and galectin-3 expression in tumors vs. adjacent normal kidney tissue
From: Galectin-1 and Galectin-3 mRNA expression in renal cell carcinoma
Patients for paired analysis | No. | % |
|---|---|---|
Total | 75 | 100% |
Patients | ||
Age (mean; ±SD) | 67 (11.8) | |
Male | 46 | 61.3% |
Female | 29 | 38.7% |
Histology | ||
Clear cell | 58 | 77.3% |
Papillary | 12 | 16% |
Chromophobe | 4 | 5.3% |
Other/notclassified | 1 | 1.3% |
Stage | ||
NA | 3 | 4% |
pT1 | 4 | 5.3% |
pT1a | 24 | 32% |
pT1b | 14 | 18.7% |
pT2 | 4 | 5.3% |
pT3 | 1 | 1.3% |
pT3a | 6 | 8% |
pT3b | 19 | 25.3% |
pT4 | 0 | 0% |
Grade | ||
G1 | 9 | 12% |
G1-2 | 11 | 14.7% |
G2 | 40 | 53.3% |
G2-3 | 6 | 8% |
G3 | 9 | 12% |
LN metastasis* | 7 | 9.3% |
Visceral metastasis* | 19 | 25.3% |
locally advanced/metastatic | ||
disease (pT3>4 and/or N/M+) | 36 | 48% |